I te 19 o Hune, i panuitia e te Center for Drug Assessment (CDE) o te National Medical Products Administration (NMPA) kua whakaarohia te IBI343 a Innovent Biologics kia whakaurua ki roto i te kaupapa tohu rongoā hou, e hāngai ana ki te rongoā i te mate pukupuku repeure kua horapa ki te rohe, kua horapa rānei, he CLDN18.2-pai, ā, kua whiwhi i te iti rawa e rua ngā rongoā pūnaha o mua.
He hononga ā-antibodi anti-CLDN18.2 (ADC) kua whakahōuhia hei tangata a IBI343. Ina herea ki ngā pūtau pukupuku e whakaatu ana i te CLDN18.2, ka uru ki roto i te ADC e whakawhirinaki ana ki te CLDN18.2, ā, ka tukuna he kawenga paitini, ka arahi ki te kino o te DNA, ā, i te mutunga ka puta te apoptosis o ngā pūtau pukupuku.
I te 9 o Hakihea, 2024, i whakaaturia ngā raraunga hou mai i te whakamātautau haumanu Wāhanga I (NCT05458219) o IBI343 i roto i te adenocarcinoma ductal pancreatic matatau (PDAC) i te Hui-ā-Tau a te Rōpū Pākehā mō te Oncology Hauora Āhia (ESMO Āhia).
E 43 ngā tūroro katoa he PDAC matatau CLDN18.2-pai i rongoatia ki te IBI343. I whakaatuhia e ngā hua he reiti urupare whāinga whānui (ORR) o te 32.6%, he reiti urupare whāinga kua whakaūtia (cORR) o te 23.3%, me te reiti whakahaere mate kua whakaūtia (cDCR) o te 81.4%. Ko te roanga waenga o te urupare (mDoR) he 7.0 marama, me te reiti DoR 6-marama o te 63%, ā, ko te oranga kore-haere whakamua (PFS) he 5.3 marama.
I tēnei wā, he maha tonu ngā whakamātautau haumanu o ngā hangarau hou hei ārai i te matepukupuku i Haina e rapu ana i ngā tūroro. Mēnā kei te hiahia koe ki te kōrero mō ngā rongoā me ngā hangarau hou, ka taea e koe te whakapā atu ki te Tari Ao o te Hōhipera Oncology Rohe Tonga o Beijing.
Tau Waea：4008803716
Email：myimmnet@163.com
Wā tuku: Pipiri-19-2025